Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12CNS 11Gastrointestinal 10Dermatologic 7Breast 5Sarcoma 3Lymphoid 2Head & Neck 2Endocrine 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1

Conditions

Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × AZD 6244 × Endocrine × Clear all
NCT02393690 2024-07-26

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Academic and Community Cancer Research United

Phase 2 Completed
60 enrolled 12 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00559949 2017-01-30

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

National Cancer Institute (NCI)

Phase 2 Completed
39 enrolled 8 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡